(0.04%) 5 519.25 points
(0.15%) 39 903 points
(0.07%) 19 764 points
(0.05%) $81.67
(0.50%) $2.83
(-0.22%) $2 339.20
(0.15%) $29.57
(0.61%) $1 007.90
(0.10%) $0.932
(-0.11%) $10.52
(0.02%) $0.788
(-0.83%) $87.27
5.48% $ 1.540
Live Chart Being Loaded With Signals
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 176 103 |
Średni wolumen | 1.61M |
Kapitalizacja rynkowa | 63.83M |
EPS | $-0.470 ( Q1 | 2024-05-09 ) |
Następna data zysków | ( $-0.420 ) 2024-08-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.820 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00500 (0.33%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-15 | Hunt Ronald | Buy | 16 500 | Option (Right to Buy) |
2024-05-15 | Boudreau Helen M | Buy | 16 500 | Option (Right to Buy) |
2024-05-15 | Liu Hui | Buy | 16 500 | Option (Right to Buy) |
2024-05-15 | Parmar Kush | Buy | 16 500 | Option (Right to Buy) |
2024-05-15 | Soteropoulos Paula | Buy | 16 500 | Option (Right to Buy) |
INSIDER POWER |
---|
92.07 |
Last 96 transactions |
Buy: 8 046 287 | Sell: 10 802 620 |
Wolumen Korelacja
Rallybio Corporation Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Rallybio Corporation Korelacja - Waluta/Towar
Rallybio Corporation Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-150 000 (0.00 %) |
EPS: | $-1.840 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-150 000 (0.00 %) |
EPS: | $-1.840 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-167 000 (0.00 %) |
EPS: | $-2.09 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-1.653 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Rallybio Corporation
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej